**Bone Sarcoma**

**Osteosarcoma**
- Localized
- Unresectable Metastatic Disease
  - IRB# 19380: An open-label, multi-institutional pilot study to assess the use of glucarpidase in patients with osteosarcoma receiving high-dose methotrexate
- Resectable Metastatic Disease
  - IRB# 19991: EAY131 (MATCH)
  - IRB# 18084: S1609 (DART)
  - IRB# 20679: SMMART: ACT
- Metastatic Disease
- Prior Therapy

**Ewing’s Sarcoma**
- Localized
- Metastatic
- Prior Therapy
- IRB# 10529: SARC24 – Regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcomas
- IRB# 20959: Phase 1, Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma Only

**SARCOMA SURVIVORS:**
- IRB# 19942: A resistance training program to improve physical function in sarcoma survivors
- IRB# 12039: Sarcoma Survivorship Registry

**CROSS-DISEASE TRIALS:**
- IRB# Sarc038: A Phase 2 Study of Regorafenib in Combination with Nivolumab in Patients with Refractory or Recurrent Osteosarcoma
- IRB# 23210: A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php